Scientists find underlying mechanisms behind chronic inflammation-associated diseases

Credit: Chen Lab, UNC School of Medicine.

(Medical Xpress)—Inflammatory response plays a major role in both health protection and disease generation. While the symptoms of disease-related inflammatory response have been know, scientists have not understood the mechanisms that underlie it.

In a paper published in Cell Reports Feb. 21, a team lead by Xian Chen, associate professor of biochemistry and biophysics and member of the UNC Lineberger Comprehensive Cancer Center, mapped the complex interactions of proteins that control inflammation at the molecular level.

The inflammatory response acts as a first line of defense for the immune system. are generated to contain infection, preventing the occurrence or spread of diseases, including . An overproduction or underproduction of these cytokines during disease-related inflammatory responses can lead to a variety of disease such as arthritis, asthma and some kinds of cancer.

The team found that chronic is mediated by the interaction of the PP2Ac and an adaptor protein of Toll-like receptors (TLRs) MyD88 in a type of the (macrophages) showing tolerance to persistent stimulation of endotoxin (LPS).

Within endotoxin-tolerized macrophages, "PP2Ac is constitutively activated and operates on a switch that exists to convert pro-inflammatory MyD88 to immunosuppressant MyD88," said Chen.

Studying interactions of the that underlies inflammation, the research team found that PP2Ac disrupts the pro-inflammatory signaling pathway mediated by the complex of MyD88 and TLR4. As a result of this disruption, both constitutively active PP2Ac and MyD88 move within the cellular nucleus, where they bound with the epigenetic machinery and alter the chromatin structure of a class of pro-inflammatory genes that leads to the silencing of this class of the genes.

"In the nucleus, in a MyD88-dependent way constitutively active PP2Ac reprograms the epigenetic machinery," said Chen.
With the discovery of PP2Ac behavior, Chen's research establishes a previously unknown link between cellular signaling and epigenetic regulation, which affects the genetic blueprint of inflammation. By mapping out the signaling pathway, as well the epigenetic machinery targeted by abnormally activated PP2Ac within the cells under chronic inflammation, the research identifies potential targets of immunomodulation for future therapies for inflammation-related disorders and cancers.

"Not only did we identify individual targets, but we also identified those interconnected targets in networks of dynamic protein interactions. That will set up the base for future network medicine, as targets on single genes and targets can have off-target side effects. To increase the precision of the drug targets, we reveal individual proteins but also their interactions as targets," said Chen.

More information: Protein Phosphatase 2A Catalytic Subunit α Plays a MyD88-Dependent, Central Role in the Gene-Specific Regulation of Endotoxin Tolerance. Cell Reports, 2013. DOI: 10.1016/j.celrep.2013.01.029

Related Stories

Penn researchers discover how key protein stops inflammation

Aug 08, 2007

Researchers at the University of Pennsylvania School of Medicine recently identified how a regulatory protein called Bcl-3 helps to control the body’s inflammation response to infection by interfering a critical biochemical ...

New insights into how immune system fights atherosclerosis

Dec 21, 2012

A study led by Columbia University Medical Center (CUMC) researchers has found that an important branch of the immune system, in reaction to the development of atherosclerotic lesions, mounts a surprisingly robust anti-inflammatory ...

Recommended for you

Phthalates heighten risk for childhood asthma

Sep 17, 2014

Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to demonstrate an association between childhood asthma and prenatal exposure to two phthalates used ...

ERS: Mepolizumab is glucocorticoid-sparing in asthma

Sep 09, 2014

(HealthDay)—For patients with eosinophilic asthma, mepolizumab has a glucocorticoid-sparing effect and reduces exacerbations when administered intravenously or subcutaneously, according to two studies published ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

nanotech_republika_pl
4 / 5 (1) Feb 23, 2013
Nice paper! People will cite it a lot, right?
Shakescene21
5 / 5 (3) Feb 23, 2013
This looks like a very big deal. Chronic inflammation causes so much pain and disability, but is not well understood. I'm not knowledgable enough to evaluate the biochemistry of this research, but if it's correct, it is a milestone event.
210
5 / 5 (2) Feb 23, 2013
This looks like a very big deal. Chronic inflammation causes so much pain and disability, but is not well understood. I'm not knowledgable enough to evaluate the biochemistry of this research, but if it's correct, it is a milestone event.


Indeed, you are exceptionally correct and you are possibly, the Master of Understatement. From the tops of our heads to the soles of our feet and every living cell and organ in-between - we truly age and aging is accelerated by the living body's inflammatory response.
I gave you five stars for 007 type cool and tried to give you another ten stars for calm-british-charm-type delivery.

Word-to-ya-muthas
tekram
5 / 5 (2) Feb 24, 2013
Anybody read the paper? It's free. MYD88 is dispensable for human resistance to common viral infections and to all but a few pyogenic bacterial infections, demonstrating a major difference between mouse and human immune responses.
http://download.c...0533.pdf